(Q35164761)

6 August 2017

1 reference

title

Thiazolidinediones -- some recent developments (English)

1 reference

6 August 2017

1

Michael Stumvoll

1 reference

PubMed ID

12831352

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

1 reference

6 August 2017

12

1 reference

6 August 2017

7

1 reference

6 August 2017

1179-1187

1 reference

Thiazolidinediones: an update.

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

21 January 2018

Insulin sensitiser drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Leptin and the regulation of body weight in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Modulation of insulin activities by leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Leptin-replacement therapy for lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Endogenous glucose production is inhibited by the adipose-derived protein Acrp30

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Adiponectin--its role in metabolism and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Peroxisome proliferator-activated receptors: nuclear control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Nuclear receptors and the control of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Troglitazone action is independent of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

The perils of portliness: causes and consequences of visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Glitazones and heart failure: critical appraisal for the clinician.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Hepatocellular injury in a patient receiving pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1179

10.1517/13543784.12.7.1179

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12831352